Drug reference

daratumumab/hyal- uronidase-fihj

Mosby’s 2024 Nursing Drug Reference

Source: Mosby’s 2024 Nursing Drug Reference
PDF pages: 352

Review source pages for extracted sections and age labels.

Overview

Names and pronunciation

(dar′a-toom′ue-mab/hye′al-ureon′ i-dase) Darzalex

PDF page 352

Functional class

Func. class.: Antineoplastic

PDF page 352

Uses

USES: Multiple myeloma

PDF page 352

Safety

Contraindications

CONTRAINDICATIONS: Hypersensitivity, pregnancy, breastfeeding

PDF page 352

Dose and formulations

Dosage and routes

DOSAGE AND ROUTES Multiple myeloma (newly diagnosed) Adult: SUBCUT with lenalidomide and dexamethasone in those ineligible for autologous stem cell transplant: Wk 1-8: daratumumab 1800 mg/hyaluroni- dase 30,000 units weekly × 8 doses; wk 9-24: daratumumab 1800 mg/hyaluroni- dase 30,000 units q2wk × 8 doses; wk 25 and thereafter: daratumumab 1800 mg/hy- aluronidase 30,000 units q4wk until dis- ease progression or unacceptable toxicity Adult: SUBCUT with bortezomib, mel- phalan, predniSONE; in those ineligi- ble for autologous stem cell transplant: wk 1-6: daratumumab 1800 mg/hyaluroni- dase 30,000 units weekly × 6 doses; wk 7-54: daratumumab 1800 mg/hyaluronidase 30,000 units q3wk × 16 doses; wk 55 and thereafter: daratumumab 1800 mg/ hyaluronidase 30,000 units q4wk until dis- ease progression or unacceptable toxicity

PDF page 352

Available forms

Available forms: solution for injection 1800 units-30000 units/15 mL HIGH ALERT

PDF page 352

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Loading InternPractice…